Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Mycobacterium avium la pacienţii HIV-pozitivi.

Profilaxia contra infecţiilor complexe cu Mycobacterium

avium la pacienţii HIV-pozitivi cu celule CD4 mai puţin

de 75 pe milimetru cub.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04AB04 RIFABUTINUM CAPS. 150 mg

MYCOBUTIN 150 mg 150 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 665 |J04AC01| ISONIAZIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04AC01 ISONIAZIDUM COMPR. 100 mg

ISONIAZIDA 100 mg 100 mg ANTIBIOTICE SA
J04AC01 ISONIAZIDUM COMPR. 300 mg

ISONIAZIDA 300 mg ANTIBIOTICE SA

J04AC01 ISONIAZIDUM SOL. INJ. 500 mg/10 ml

IZONIAZIDA 500 mg 500 mg/10 ml TERAPIA SA

________________________________________________________________________________
______________________________________________________________________________

| 666 |J04AK01| PYRAZINAMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04AK01 PYRAZINAMIDUM COMPR. 500 mg

PIRAZINAMIDA ANTIBIOTICE 500 mg ANTIBIOTICE S.A.

500 mg

________________________________________________________________________________
______________________________________________________________________________

| 667 |J04AK02| ETHAMBUTOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04AK02 ETHAMBUTOLUM COMPR. FILM. 250 mg

ETAMBUTOL 250 mg 250 mg ANTIBIOTICE SA

________________________________________________________________________________

______________________________________________________________________________

| 668 |J04AM02| COMBINATII (RIFAMPICINUM + IZONIAZIDUM) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04AM02 COMBINATII CAPS. 300 mg + 150 mg

(RIFAMPICINUM +

IZONIAZIDUM)

SINERDOL ISO 300 mg + 150 mg ANTIBIOTICE SA

________________________________________________________________________________

______________________________________________________________________________

| 669 |J05AB01| ACICLOVIRUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB01 ACICLOVIRUM CAPS. 200 mg

ACICLOVIR 200 mg 200 mg ARENA GROUP SA

EUVIROX 200 mg 200 mg EUROPHARM SA

J05AB01 ACICLOVIRUM COMPR. 200 mg

ACICLOVIR 200 mg 200 mg TERAPIA SA

CLOVIRAL 200 mg 200 mg ANTIBIOTICE SA

ZOVIRAX 200 mg GLAXO WELLCOME FOUNDATION

LTD.
J05AB01 ACICLOVIRUM COMPR. DISP. 200 mg

ACICLOVIR 200 mg 200 mg OZONE LABORATORIES LTD.

LOVIR 200 mg 200 mg RANBAXY UK LIMITED
J05AB01 ACICLOVIRUM PULB. PT. SOL. 250 mg

INJ./PERF.

VIROLEX 250 mg KRKA D.D. NOVO MESTO
J05AB01 ACICLOVIRUM CAPS. 400 mg

ACICLOVIR 400 mg 400 mg ARENA GROUP S.A.

J05AB01 ACICLOVIRUM COMPR. 400 mg

ACICLOVIR 400 mg 400 mg EGIS PHARMACEUTICALS

P.L.C.

J05AB01 ACICLOVIRUM COMPR. FILM. 400 mg

ACIKLOVIR 400 mg A & G MED TRADING S.R.L.

________________________________________________________________________________

______________________________________________________________________________

| 670 |J05AB04| RIBAVIRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB04 RIBAVIRINUM CAPS. 200 mg

REBETOL 200 mg 200 mg SP EUROPE
J05AB04 RIBAVIRINUM COMPR. FILM. 200 mg

COPEGUS(R) 200 mg ROCHE ROMANIA SRL

________________________________________________________________________________
______________________________________________________________________________

| 671 |J05AB06| GANCICLOVIRUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Infecţii severe cu citomegalovirus (CMV) la pacienţi imunocompromişi inclusiv cu localizare oculară.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB06 GANCICLOVIRUM LIOF. PT. SOL. INJ. 500 mg

CYMEVENE 500 mg ROCHE ROMANIA S.R.L.

________________________________________________________________________________

______________________________________________________________________________

| 672 |J05AB11| VALACYCLOVIRUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB11 VALACYCLOVIRUM COMPR. FILM. 500 mg

VALTREX 500 mg 500 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 673 |J05AB14| VALGANCICLOVIRUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg

VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL

________________________________________________________________________________

______________________________________________________________________________

| 674 |J05ABN1| BRIVUDINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05ABN1 BRIVUDINUM COMPR. 125 mg

BRIVAL(R) 125 mg BERLIN CHEME AG MENARINI

GROUP

________________________________________________________________________________
______________________________________________________________________________

| 676 |J06BB16| PALIVIZUMABUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Prevenirea bolilor severe ale tractului respirator inferior care necesită spitalizare, provocate de virusul sinciţial respirator (VSR) la copii născuţi la 35 săptămâni de gestaţie sau mai puţin şi cu vârsta mai mică de 6 luni la începutul sezonului de îmbolnăviri cu VSR sau la copii cu vârsta mai mică de 2 ani care au necesitat tratament pentru displazie bronhopulmonară în ultimele 6 luni.